Gautam N Shenoy1, Maulasri Bhatta2, Jenni L Loyall1, Raymond J Kelleher1, Joel M Bernstein3, Richard B Bankert1. 1. Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo , Buffalo, New York, USA. 2. Immune Modulatory Therapies LLC , Eden, New York, USA. 3. Department of Otolaryngology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo , Buffalo, New York, USA.
Abstract
Background: T cells present in chronic inflammatory tissues such as nasal polyps (from chronic rhinosinusitis patients) have been demonstrated to be hypo-responsive to activation via the TCR, similar to tumor-specific T cells in multiple different human tumor microenvironments. While immunosuppressive exosomes have been known to contribute to the failure of the tumor-associated T cells to respond optimally to activation stimuli, it is not known whether they play a similar role in chronic inflammatory microenvironments. In the current study, we investigate whether exosomes derived from chronic inflammatory microenvironments contribute to the immune suppression of T cells. Methods: Exosomes were isolated by ultracentrifugation and characterized by size and composition using nanoparticle tracking analysis, scanning electron microscopy, antibody arrays and flow exometry. Immunosuppressive ability of the exosomes was measured by quantifying its effect on activation of T cells, using nuclear translocation of NFκB as an activation endpoint. Results: Exosomes were isolated and characterized from two different types of chronic inflammatory tissues - nasal polyps from chronic rhinosinusitis patients and synovial fluid from rheumatoid arthritis patients. These exosomes arrest the activation of T cells stimulated via the TCR. This immune suppression, like that which is seen in tumor microenvironments, is dependent in part upon a lipid, ganglioside GD3, which is expressed on the exosomal surface. Conclusion: Immunosuppressive exosomes present in non-malignant chronic inflammatory tissues represent a new T cell checkpoint, and potentially represent a novel therapeutic target to enhance the response to current therapies and prevent disease recurrences.
Background: T cells present in chronic inflammatory tissues such as nasal polyps (from chronic rhinosinusitispatients) have been demonstrated to be hypo-responsive to activation via the TCR, similar to tumor-specific T cells in multiple different humantumor microenvironments. While immunosuppressive exosomes have been known to contribute to the failure of the tumor-associated T cells to respond optimally to activation stimuli, it is not known whether they play a similar role in chronic inflammatory microenvironments. In the current study, we investigate whether exosomes derived from chronic inflammatory microenvironments contribute to the immune suppression of T cells. Methods: Exosomes were isolated by ultracentrifugation and characterized by size and composition using nanoparticle tracking analysis, scanning electron microscopy, antibody arrays and flow exometry. Immunosuppressive ability of the exosomes was measured by quantifying its effect on activation of T cells, using nuclear translocation of NFκB as an activation endpoint. Results: Exosomes were isolated and characterized from two different types of chronic inflammatory tissues - nasal polyps from chronic rhinosinusitispatients and synovial fluid from rheumatoid arthritispatients. These exosomes arrest the activation of T cells stimulated via the TCR. This immune suppression, like that which is seen in tumor microenvironments, is dependent in part upon a lipid, gangliosideGD3, which is expressed on the exosomal surface. Conclusion: Immunosuppressive exosomes present in non-malignant chronic inflammatory tissues represent a new T cell checkpoint, and potentially represent a novel therapeutic target to enhance the response to current therapies and prevent disease recurrences.
Authors: Benjamin A Olenchock; Rishu Guo; Jeffery H Carpenter; Martha Jordan; Matthew K Topham; Gary A Koretzky; Xiao-Ping Zhong Journal: Nat Immunol Date: 2006-10-08 Impact factor: 25.606
Authors: S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet Journal: J Clin Invest Date: 1998-11-01 Impact factor: 14.808
Authors: Michelle R Simpson-Abelson; Jenni L Loyall; Heather K Lehman; Jennifer L Barnas; Hans Minderman; Kieran L O'Loughlin; Paul K Wallace; Thaddeus C George; Peng Peng; Raymond J Kelleher; Kunle Odunsi; Richard B Bankert Journal: Cancer Immun Date: 2013-07-15
Authors: Raymond J Kelleher; Sathy Balu-Iyer; Jenni Loyall; Anthony J Sacca; Gautam N Shenoy; Peng Peng; Vandana Iyer; Anas M Fathallah; Charles S Berenson; Paul K Wallace; Joseph Tario; Kunle Odunsi; Richard B Bankert Journal: Cancer Immunol Res Date: 2015-06-25 Impact factor: 11.151
Authors: Dawn M Jelley-Gibbs; John P Dibble; Svetlana Filipson; Laura Haynes; Roslyn A Kemp; Susan L Swain Journal: J Exp Med Date: 2005-03-28 Impact factor: 14.307
Authors: Cecilia Lässer; Serena E O'Neil; Ganesh V Shelke; Carina Sihlbom; Sara F Hansson; Yong Song Gho; Bo Lundbäck; Jan Lötvall Journal: J Transl Med Date: 2016-06-20 Impact factor: 5.531
Authors: Gautam N Shenoy; Christopher J Greene; Maulasri Bhatta; Miren L Baroja; Jenni L Loyall; Sathy V Balu-Iyer; Raymond J Kelleher; Beatriz M Carreno; Gerald P Linette; Leonard D Shultz; Richard B Bankert Journal: Clin Transl Immunology Date: 2021-02-02
Authors: Maulasri Bhatta; Gautam N Shenoy; Jenni L Loyall; Brian D Gray; Meghana Bapardekar; Alexis Conway; Hans Minderman; Raymond J Kelleher; Beatriz M Carreno; Gerald Linette; Leonard D Shultz; Kunle Odunsi; Sathy V Balu-Iyer; Koon Yan Pak; Richard B Bankert Journal: J Immunother Cancer Date: 2021-10 Impact factor: 13.751